With WHO prequalification, global health organizations can consider the Aptima HIV-1 Quant Dx for public-sector procurement in resource-limited countries.
The company said it will use the proceeds from the offering for general corporate and working capital purposes.
The firm intends to use the net proceeds of the offering and available cash to retire its remaining convertible notes when they become callable.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
The firm said it intends to use net proceeds from the issuance of the notes for general corporate purposes.
The offering consists of two tranches of $600 million each, and the firm plans to use the net proceeds for general corporate purposes, including the repayment of outstanding senior notes due on Aug. 23.
The company is aiming to raise $1.5 billion through the issuance of 3.2% senior notes due 2027 and 4.1% senior notes due 2047.
The company plans to use the net proceeds to partially fund the $7.2 billion acquisition of pharmaceutical contract development and manufacturing firm Patheon.
The company said it will use the funds to develop antimicrobial therapeutics based on CRISPR-Cas3 technology.
The firm's European subsidiary is offering the new senior notes to repay, in part, all outstanding aggregate principal amounts on senior notes due later this month.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.